In First Phase 3 Trial, Merck ’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first Phase 3 study results for V212, the company ’s
investigational inactivated varicella zoster virus vaccine (VZV) for the
prevention of herpes zoster or HZ, also known as shingles, in
immunocompromised patients.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSkip Irvine, 267-305-0338orInvestors:Amy Klug, 908-740-1898orMichael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
More News: Herpes | Merck | Pharmaceuticals | Shingles | Shingles (Herpes Zoster) Vaccine | Study | Vaccines | Varicella-Zoster Virus Vaccine